Flexion Therapeutics Announces Appointment of John Magee as Vice President of Sales
September 29 2016 - 8:30AM
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it
has appointed John Magee as Vice President of Sales, the latest of
several key appointments to the company’s leadership team.
Mr. Magee has more than 35 years of experience as a sales
professional. Prior to joining Flexion, he was head of U.S. sales
for the rare disease unit of Shire Pharmaceuticals, where he also
served as U.S. sales director for its renal business. Previously,
he held senior sales positions at Esprit Pharma and Bayer
Corporation. He has a Bachelor’s degree in biology and anthropology
from Hamilton College, and completed MBA courses at the Rochester
Institute of Technology. Mr. Magee joins Flexion as the
company prepares to submit a planned new drug application (NDA) in
the fourth quarter of 2016 to the U.S. Food and Drug Administration
(FDA) for its drug candidate Zilretta™ (also known as FX006), a
potential treatment for patients with moderate to severe knee
osteoarthritis (OA) pain.
Michael Clayman, MD, President and Chief Executive Officer of
Flexion, stated, “John is another excellent addition to the Flexion
team as we continue planning for Zilretta’s commercial launch.
During his time in the rare disease unit of Shire, he helped to
achieve revenue growth of more than $1 billion. John’s experience
in successfully recruiting and managing pharmaceutical sales
organizations will play a key role for us as we prepare for the
potential launch and commercialization of our new investigational
treatment in the marketplace in 2017.”
About Flexion Therapeutics
Flexion is a specialty pharmaceutical company focused on the
development and commercialization of novel, local therapies for the
treatment of patients with musculoskeletal conditions, beginning
with OA. The company's lead product candidate, Zilretta, is being
investigated for its potential to provide improved analgesic
therapy for the millions of U.S. patients who receive
intra-articular (IA) injections for knee OA annually.
Forward-Looking Statements
Statements in this press release regarding matters that are not
historical facts, including, but not limited to, statements
relating to the future of Flexion; our plans for, and the expected
timing of, our Zilretta NDA submission with the FDA; our plans to
commercialize Zilretta[, including the expected timing of
commercial launch for Zilretta]; and the potential therapeutic and
other benefits of Zilretta, are forward-looking statements. These
forward-looking statements are based on management's expectations
and assumptions as of the date of this press release and are
subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those expressed or implied
by such statements. These risks and uncertainties include, without
limitation, risks associated with the process of discovering,
developing, manufacturing and obtaining regulatory approval for
drugs that are safe and effective for use as human therapeutics;
our reliance on third parties to manufacture and conduct clinical
trials of Zilretta, which could delay or limit its future
development or regulatory approval; our ability to meet anticipated
regulatory filing dates and commercial launch plans for Zilretta;
the fact that we will require additional capital, including prior
to commercializing Zilretta or any other product candidates, and
may be unable to obtain such additional capital in sufficient
amounts or on terms acceptable to us; the risk that we may not be
able to maintain and enforce our intellectual property, including
intellectual property related to Zilretta; competition from
alternative therapies; regulatory developments and safety issues,
including difficulties or delays in obtaining regulatory approvals
to market Zilretta; the risk that the FDA and foreign regulatory
authorities may not agree with our interpretation of the data from
our clinical trials of Zilretta and may require us to conduct
additional clinical trials; Zilretta may not receive regulatory
approval or be successfully commercialized, including as a result
of the FDA’s or other regulatory authorities’ decisions regarding
labeling and other matters that could affect its availability or
commercial potential; risks related to key employees, markets,
economic conditions, health care reform, prices and reimbursement
rates; and other risks and uncertainties described in our filings
with the Securities and Exchange Commission (SEC), including under
the heading "Risk Factors" in our most recent Annual Report on Form
10-K and subsequent filings with the SEC. The forward-looking
statements in this press release speak only as of the date of this
press release, and we undertake no obligation to update or revise
any of the statements. We caution investors not to place
considerable reliance on the forward-looking statements contained
in this press release.
Investor Contact
David Carey
Lazar Partners LTD
T: 212-867-1768
dcarey@lazarpartners.com
PR Contact
Danielle Lewis
Lazar Partners LTD
T: 212-843-0211
dlewis@lazarpartners.com
Corporate Contact
Fred Driscoll
Chief Financial Officer
Flexion Therapeutics, Inc.
T: 781-305-7763
fdriscoll@flexiontherapeutics.com
Flexion Therapeutics (NASDAQ:FLXN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Flexion Therapeutics (NASDAQ:FLXN)
Historical Stock Chart
From Apr 2023 to Apr 2024